Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer

Interactions of both the innate and the adaptive immune system with tumors are complex and often influence courses and therapeutic treatments in unanticipated ways. Based on the concept that CD8<sup<+</sup<T cells can mediate important antitumor effects, several therapies now aim to amplify their specific activity. A subpopulation of CD8<sup<+</sup< tissue-resident T lymphocytes that express the α<sub<E</sub<(CD103)β<sub<7</sub< integrin has raised particular interest. This receptor presumably contributes to the recruitment and retention of tumor-infiltrating immune cells through interaction with its ligand, E-cadherin. It appears to have regulatory functions and is thought to be a component of some immunological synapses. In TGF-rich environments, the α<sub<E</sub<(CD103)β<sub<7</sub</E-cadherin-interaction enhances the binding strength between tumor cells and infiltrating T lymphocytes. This activity facilitates the release of lytic granule contents and cytokines as well as further immune responses and the killing of target cells. Expression of α<sub<E</sub<(CD103)β<sub<7</sub< in some tumors is associated with a rather favorable prognosis, perhaps with the notable exception of squamous cell carcinoma of the skin. Although epithelial skin tumors are by far the most common tumors of fair-skinned people, there have been very few studies on the distribution of α<sub<E</sub<(CD103)β<sub<7</sub< expressing cells in these neoplasms. Given this background, we describe here that α<sub<E</sub<(CD103)β<sub<7</sub< is scarcely present in basal cell carcinomas, but much more abundant in squamous cell carcinomas with heterogeneous distribution. Notwithstanding a substantial number of studies, the role of α<sub<E</sub<(CD103)β<sub<7</sub< in the tumor context is still far from clear. Here, we summarize the essential current knowledge on α<sub<E</sub<(CD103)β<sub<7</sub< and outline that it is worthwhile to further explore this intriguing receptor with regard to the pathophysiology, therapy, and prognosis of solid tumors. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Johanna C. Hoffmann [verfasserIn] Michael P. Schön [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	CD103 integrin α E-cadherin T immunotherapy

Übergeordnetes Werk:	In: Cancers - MDPI AG, 2010, 13(2021), 24, p 6211
Übergeordnetes Werk:	volume:13 ; year:2021 ; number:24, p 6211

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/cancers13246211

Katalog-ID:	DOAJ018726534

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ018726534
003	DE-627
005	20240412095357.0
007	cr uuu---uuuuu
008	230226s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/cancers13246211 \|2 doi
035			\|a (DE-627)DOAJ018726534
035			\|a (DE-599)DOAJ14c9772ee521489ab59b771bb99b4637
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Johanna C. Hoffmann \|e verfasserin \|4 aut
245	1	0	\|a Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Interactions of both the innate and the adaptive immune system with tumors are complex and often influence courses and therapeutic treatments in unanticipated ways. Based on the concept that CD8<sup<+</sup<T cells can mediate important antitumor effects, several therapies now aim to amplify their specific activity. A subpopulation of CD8<sup<+</sup< tissue-resident T lymphocytes that express the α<sub<E</sub<(CD103)β<sub<7</sub< integrin has raised particular interest. This receptor presumably contributes to the recruitment and retention of tumor-infiltrating immune cells through interaction with its ligand, E-cadherin. It appears to have regulatory functions and is thought to be a component of some immunological synapses. In TGF-rich environments, the α<sub<E</sub<(CD103)β<sub<7</sub</E-cadherin-interaction enhances the binding strength between tumor cells and infiltrating T lymphocytes. This activity facilitates the release of lytic granule contents and cytokines as well as further immune responses and the killing of target cells. Expression of α<sub<E</sub<(CD103)β<sub<7</sub< in some tumors is associated with a rather favorable prognosis, perhaps with the notable exception of squamous cell carcinoma of the skin. Although epithelial skin tumors are by far the most common tumors of fair-skinned people, there have been very few studies on the distribution of α<sub<E</sub<(CD103)β<sub<7</sub< expressing cells in these neoplasms. Given this background, we describe here that α<sub<E</sub<(CD103)β<sub<7</sub< is scarcely present in basal cell carcinomas, but much more abundant in squamous cell carcinomas with heterogeneous distribution. Notwithstanding a substantial number of studies, the role of α<sub<E</sub<(CD103)β<sub<7</sub< in the tumor context is still far from clear. Here, we summarize the essential current knowledge on α<sub<E</sub<(CD103)β<sub<7</sub< and outline that it is worthwhile to further explore this intriguing receptor with regard to the pathophysiology, therapy, and prognosis of solid tumors.
650		4	\|a CD103
650		4	\|a integrin
650		4	\|a α<sub<E</sub<(CD103)β<sub<7</sub<
650		4	\|a E-cadherin
650		4	\|a T<sub<RM</sub< cells
650		4	\|a immunotherapy
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Michael P. Schön \|e verfasserin \|4 aut
773	0	8	\|i In \|t Cancers \|d MDPI AG, 2010 \|g 13(2021), 24, p 6211 \|w (DE-627)614095670 \|w (DE-600)2527080-1 \|x 20726694 \|7 nnns
773	1	8	\|g volume:13 \|g year:2021 \|g number:24, p 6211
856	4	0	\|u https://doi.org/10.3390/cancers13246211 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/14c9772ee521489ab59b771bb99b4637 \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2072-6694/13/24/6211 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2072-6694 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 13 \|j 2021 \|e 24, p 6211

Indexfelder

author_variant	j c h jch m p s mps
matchkey_str	article:20726694:2021----::nernueuc13u7uiei
hierarchy_sort_str	2021
callnumber-subject-code	RC
publishDate	2021
allfields	10.3390/cancers13246211 doi (DE-627)DOAJ018726534 (DE-599)DOAJ14c9772ee521489ab59b771bb99b4637 DE-627 ger DE-627 rakwb eng RC254-282 Johanna C. Hoffmann verfasserin aut Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Interactions of both the innate and the adaptive immune system with tumors are complex and often influence courses and therapeutic treatments in unanticipated ways. Based on the concept that CD8<sup<+</sup<T cells can mediate important antitumor effects, several therapies now aim to amplify their specific activity. A subpopulation of CD8<sup<+</sup< tissue-resident T lymphocytes that express the α<sub<E</sub<(CD103)β<sub<7</sub< integrin has raised particular interest. This receptor presumably contributes to the recruitment and retention of tumor-infiltrating immune cells through interaction with its ligand, E-cadherin. It appears to have regulatory functions and is thought to be a component of some immunological synapses. In TGF-rich environments, the α<sub<E</sub<(CD103)β<sub<7</sub</E-cadherin-interaction enhances the binding strength between tumor cells and infiltrating T lymphocytes. This activity facilitates the release of lytic granule contents and cytokines as well as further immune responses and the killing of target cells. Expression of α<sub<E</sub<(CD103)β<sub<7</sub< in some tumors is associated with a rather favorable prognosis, perhaps with the notable exception of squamous cell carcinoma of the skin. Although epithelial skin tumors are by far the most common tumors of fair-skinned people, there have been very few studies on the distribution of α<sub<E</sub<(CD103)β<sub<7</sub< expressing cells in these neoplasms. Given this background, we describe here that α<sub<E</sub<(CD103)β<sub<7</sub< is scarcely present in basal cell carcinomas, but much more abundant in squamous cell carcinomas with heterogeneous distribution. Notwithstanding a substantial number of studies, the role of α<sub<E</sub<(CD103)β<sub<7</sub< in the tumor context is still far from clear. Here, we summarize the essential current knowledge on α<sub<E</sub<(CD103)β<sub<7</sub< and outline that it is worthwhile to further explore this intriguing receptor with regard to the pathophysiology, therapy, and prognosis of solid tumors. CD103 integrin α<sub<E</sub<(CD103)β<sub<7</sub< E-cadherin T<sub<RM</sub< cells immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens Michael P. Schön verfasserin aut In Cancers MDPI AG, 2010 13(2021), 24, p 6211 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:13 year:2021 number:24, p 6211 https://doi.org/10.3390/cancers13246211 kostenfrei https://doaj.org/article/14c9772ee521489ab59b771bb99b4637 kostenfrei https://www.mdpi.com/2072-6694/13/24/6211 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2021 24, p 6211
spelling	10.3390/cancers13246211 doi (DE-627)DOAJ018726534 (DE-599)DOAJ14c9772ee521489ab59b771bb99b4637 DE-627 ger DE-627 rakwb eng RC254-282 Johanna C. Hoffmann verfasserin aut Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Interactions of both the innate and the adaptive immune system with tumors are complex and often influence courses and therapeutic treatments in unanticipated ways. Based on the concept that CD8<sup<+</sup<T cells can mediate important antitumor effects, several therapies now aim to amplify their specific activity. A subpopulation of CD8<sup<+</sup< tissue-resident T lymphocytes that express the α<sub<E</sub<(CD103)β<sub<7</sub< integrin has raised particular interest. This receptor presumably contributes to the recruitment and retention of tumor-infiltrating immune cells through interaction with its ligand, E-cadherin. It appears to have regulatory functions and is thought to be a component of some immunological synapses. In TGF-rich environments, the α<sub<E</sub<(CD103)β<sub<7</sub</E-cadherin-interaction enhances the binding strength between tumor cells and infiltrating T lymphocytes. This activity facilitates the release of lytic granule contents and cytokines as well as further immune responses and the killing of target cells. Expression of α<sub<E</sub<(CD103)β<sub<7</sub< in some tumors is associated with a rather favorable prognosis, perhaps with the notable exception of squamous cell carcinoma of the skin. Although epithelial skin tumors are by far the most common tumors of fair-skinned people, there have been very few studies on the distribution of α<sub<E</sub<(CD103)β<sub<7</sub< expressing cells in these neoplasms. Given this background, we describe here that α<sub<E</sub<(CD103)β<sub<7</sub< is scarcely present in basal cell carcinomas, but much more abundant in squamous cell carcinomas with heterogeneous distribution. Notwithstanding a substantial number of studies, the role of α<sub<E</sub<(CD103)β<sub<7</sub< in the tumor context is still far from clear. Here, we summarize the essential current knowledge on α<sub<E</sub<(CD103)β<sub<7</sub< and outline that it is worthwhile to further explore this intriguing receptor with regard to the pathophysiology, therapy, and prognosis of solid tumors. CD103 integrin α<sub<E</sub<(CD103)β<sub<7</sub< E-cadherin T<sub<RM</sub< cells immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens Michael P. Schön verfasserin aut In Cancers MDPI AG, 2010 13(2021), 24, p 6211 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:13 year:2021 number:24, p 6211 https://doi.org/10.3390/cancers13246211 kostenfrei https://doaj.org/article/14c9772ee521489ab59b771bb99b4637 kostenfrei https://www.mdpi.com/2072-6694/13/24/6211 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2021 24, p 6211
allfields_unstemmed	10.3390/cancers13246211 doi (DE-627)DOAJ018726534 (DE-599)DOAJ14c9772ee521489ab59b771bb99b4637 DE-627 ger DE-627 rakwb eng RC254-282 Johanna C. Hoffmann verfasserin aut Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Interactions of both the innate and the adaptive immune system with tumors are complex and often influence courses and therapeutic treatments in unanticipated ways. Based on the concept that CD8<sup<+</sup<T cells can mediate important antitumor effects, several therapies now aim to amplify their specific activity. A subpopulation of CD8<sup<+</sup< tissue-resident T lymphocytes that express the α<sub<E</sub<(CD103)β<sub<7</sub< integrin has raised particular interest. This receptor presumably contributes to the recruitment and retention of tumor-infiltrating immune cells through interaction with its ligand, E-cadherin. It appears to have regulatory functions and is thought to be a component of some immunological synapses. In TGF-rich environments, the α<sub<E</sub<(CD103)β<sub<7</sub</E-cadherin-interaction enhances the binding strength between tumor cells and infiltrating T lymphocytes. This activity facilitates the release of lytic granule contents and cytokines as well as further immune responses and the killing of target cells. Expression of α<sub<E</sub<(CD103)β<sub<7</sub< in some tumors is associated with a rather favorable prognosis, perhaps with the notable exception of squamous cell carcinoma of the skin. Although epithelial skin tumors are by far the most common tumors of fair-skinned people, there have been very few studies on the distribution of α<sub<E</sub<(CD103)β<sub<7</sub< expressing cells in these neoplasms. Given this background, we describe here that α<sub<E</sub<(CD103)β<sub<7</sub< is scarcely present in basal cell carcinomas, but much more abundant in squamous cell carcinomas with heterogeneous distribution. Notwithstanding a substantial number of studies, the role of α<sub<E</sub<(CD103)β<sub<7</sub< in the tumor context is still far from clear. Here, we summarize the essential current knowledge on α<sub<E</sub<(CD103)β<sub<7</sub< and outline that it is worthwhile to further explore this intriguing receptor with regard to the pathophysiology, therapy, and prognosis of solid tumors. CD103 integrin α<sub<E</sub<(CD103)β<sub<7</sub< E-cadherin T<sub<RM</sub< cells immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens Michael P. Schön verfasserin aut In Cancers MDPI AG, 2010 13(2021), 24, p 6211 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:13 year:2021 number:24, p 6211 https://doi.org/10.3390/cancers13246211 kostenfrei https://doaj.org/article/14c9772ee521489ab59b771bb99b4637 kostenfrei https://www.mdpi.com/2072-6694/13/24/6211 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2021 24, p 6211
allfieldsGer	10.3390/cancers13246211 doi (DE-627)DOAJ018726534 (DE-599)DOAJ14c9772ee521489ab59b771bb99b4637 DE-627 ger DE-627 rakwb eng RC254-282 Johanna C. Hoffmann verfasserin aut Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Interactions of both the innate and the adaptive immune system with tumors are complex and often influence courses and therapeutic treatments in unanticipated ways. Based on the concept that CD8<sup<+</sup<T cells can mediate important antitumor effects, several therapies now aim to amplify their specific activity. A subpopulation of CD8<sup<+</sup< tissue-resident T lymphocytes that express the α<sub<E</sub<(CD103)β<sub<7</sub< integrin has raised particular interest. This receptor presumably contributes to the recruitment and retention of tumor-infiltrating immune cells through interaction with its ligand, E-cadherin. It appears to have regulatory functions and is thought to be a component of some immunological synapses. In TGF-rich environments, the α<sub<E</sub<(CD103)β<sub<7</sub</E-cadherin-interaction enhances the binding strength between tumor cells and infiltrating T lymphocytes. This activity facilitates the release of lytic granule contents and cytokines as well as further immune responses and the killing of target cells. Expression of α<sub<E</sub<(CD103)β<sub<7</sub< in some tumors is associated with a rather favorable prognosis, perhaps with the notable exception of squamous cell carcinoma of the skin. Although epithelial skin tumors are by far the most common tumors of fair-skinned people, there have been very few studies on the distribution of α<sub<E</sub<(CD103)β<sub<7</sub< expressing cells in these neoplasms. Given this background, we describe here that α<sub<E</sub<(CD103)β<sub<7</sub< is scarcely present in basal cell carcinomas, but much more abundant in squamous cell carcinomas with heterogeneous distribution. Notwithstanding a substantial number of studies, the role of α<sub<E</sub<(CD103)β<sub<7</sub< in the tumor context is still far from clear. Here, we summarize the essential current knowledge on α<sub<E</sub<(CD103)β<sub<7</sub< and outline that it is worthwhile to further explore this intriguing receptor with regard to the pathophysiology, therapy, and prognosis of solid tumors. CD103 integrin α<sub<E</sub<(CD103)β<sub<7</sub< E-cadherin T<sub<RM</sub< cells immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens Michael P. Schön verfasserin aut In Cancers MDPI AG, 2010 13(2021), 24, p 6211 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:13 year:2021 number:24, p 6211 https://doi.org/10.3390/cancers13246211 kostenfrei https://doaj.org/article/14c9772ee521489ab59b771bb99b4637 kostenfrei https://www.mdpi.com/2072-6694/13/24/6211 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2021 24, p 6211
allfieldsSound	10.3390/cancers13246211 doi (DE-627)DOAJ018726534 (DE-599)DOAJ14c9772ee521489ab59b771bb99b4637 DE-627 ger DE-627 rakwb eng RC254-282 Johanna C. Hoffmann verfasserin aut Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Interactions of both the innate and the adaptive immune system with tumors are complex and often influence courses and therapeutic treatments in unanticipated ways. Based on the concept that CD8<sup<+</sup<T cells can mediate important antitumor effects, several therapies now aim to amplify their specific activity. A subpopulation of CD8<sup<+</sup< tissue-resident T lymphocytes that express the α<sub<E</sub<(CD103)β<sub<7</sub< integrin has raised particular interest. This receptor presumably contributes to the recruitment and retention of tumor-infiltrating immune cells through interaction with its ligand, E-cadherin. It appears to have regulatory functions and is thought to be a component of some immunological synapses. In TGF-rich environments, the α<sub<E</sub<(CD103)β<sub<7</sub</E-cadherin-interaction enhances the binding strength between tumor cells and infiltrating T lymphocytes. This activity facilitates the release of lytic granule contents and cytokines as well as further immune responses and the killing of target cells. Expression of α<sub<E</sub<(CD103)β<sub<7</sub< in some tumors is associated with a rather favorable prognosis, perhaps with the notable exception of squamous cell carcinoma of the skin. Although epithelial skin tumors are by far the most common tumors of fair-skinned people, there have been very few studies on the distribution of α<sub<E</sub<(CD103)β<sub<7</sub< expressing cells in these neoplasms. Given this background, we describe here that α<sub<E</sub<(CD103)β<sub<7</sub< is scarcely present in basal cell carcinomas, but much more abundant in squamous cell carcinomas with heterogeneous distribution. Notwithstanding a substantial number of studies, the role of α<sub<E</sub<(CD103)β<sub<7</sub< in the tumor context is still far from clear. Here, we summarize the essential current knowledge on α<sub<E</sub<(CD103)β<sub<7</sub< and outline that it is worthwhile to further explore this intriguing receptor with regard to the pathophysiology, therapy, and prognosis of solid tumors. CD103 integrin α<sub<E</sub<(CD103)β<sub<7</sub< E-cadherin T<sub<RM</sub< cells immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens Michael P. Schön verfasserin aut In Cancers MDPI AG, 2010 13(2021), 24, p 6211 (DE-627)614095670 (DE-600)2527080-1 20726694 nnns volume:13 year:2021 number:24, p 6211 https://doi.org/10.3390/cancers13246211 kostenfrei https://doaj.org/article/14c9772ee521489ab59b771bb99b4637 kostenfrei https://www.mdpi.com/2072-6694/13/24/6211 kostenfrei https://doaj.org/toc/2072-6694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2021 24, p 6211
language	English
source	In Cancers 13(2021), 24, p 6211 volume:13 year:2021 number:24, p 6211
sourceStr	In Cancers 13(2021), 24, p 6211 volume:13 year:2021 number:24, p 6211
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	CD103 integrin α<sub<E</sub<(CD103)β<sub<7</sub< E-cadherin T<sub<RM</sub< cells immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Cancers
authorswithroles_txt_mv	Johanna C. Hoffmann @@aut@@ Michael P. Schön @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	614095670
id	DOAJ018726534
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ018726534</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412095357.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers13246211</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ018726534</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ14c9772ee521489ab59b771bb99b4637</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Johanna C. Hoffmann</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Interactions of both the innate and the adaptive immune system with tumors are complex and often influence courses and therapeutic treatments in unanticipated ways. Based on the concept that CD8<sup<+</sup<T cells can mediate important antitumor effects, several therapies now aim to amplify their specific activity. A subpopulation of CD8<sup<+</sup< tissue-resident T lymphocytes that express the α<sub<E</sub<(CD103)β<sub<7</sub< integrin has raised particular interest. This receptor presumably contributes to the recruitment and retention of tumor-infiltrating immune cells through interaction with its ligand, E-cadherin. It appears to have regulatory functions and is thought to be a component of some immunological synapses. In TGF-rich environments, the α<sub<E</sub<(CD103)β<sub<7</sub</E-cadherin-interaction enhances the binding strength between tumor cells and infiltrating T lymphocytes. This activity facilitates the release of lytic granule contents and cytokines as well as further immune responses and the killing of target cells. Expression of α<sub<E</sub<(CD103)β<sub<7</sub< in some tumors is associated with a rather favorable prognosis, perhaps with the notable exception of squamous cell carcinoma of the skin. Although epithelial skin tumors are by far the most common tumors of fair-skinned people, there have been very few studies on the distribution of α<sub<E</sub<(CD103)β<sub<7</sub< expressing cells in these neoplasms. Given this background, we describe here that α<sub<E</sub<(CD103)β<sub<7</sub< is scarcely present in basal cell carcinomas, but much more abundant in squamous cell carcinomas with heterogeneous distribution. Notwithstanding a substantial number of studies, the role of α<sub<E</sub<(CD103)β<sub<7</sub< in the tumor context is still far from clear. Here, we summarize the essential current knowledge on α<sub<E</sub<(CD103)β<sub<7</sub< and outline that it is worthwhile to further explore this intriguing receptor with regard to the pathophysiology, therapy, and prognosis of solid tumors.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CD103</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">integrin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">α<sub<E</sub<(CD103)β<sub<7</sub<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">E-cadherin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">T<sub<RM</sub< cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael P. Schön</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">13(2021), 24, p 6211</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:24, p 6211</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers13246211</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/14c9772ee521489ab59b771bb99b4637</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/13/24/6211</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2021</subfield><subfield code="e">24, p 6211</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Johanna C. Hoffmann
spellingShingle	Johanna C. Hoffmann misc RC254-282 misc CD103 misc integrin misc α<sub<E</sub<(CD103)β<sub<7</sub< misc E-cadherin misc T<sub<RM</sub< cells misc immunotherapy misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer
authorStr	Johanna C. Hoffmann
ppnlink_with_tag_str_mv	@@773@@(DE-627)614095670
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	20726694
topic_title	RC254-282 Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer CD103 integrin α<sub<E</sub<(CD103)β<sub<7</sub< E-cadherin T<sub<RM</sub< cells immunotherapy
topic	misc RC254-282 misc CD103 misc integrin misc α<sub<E</sub<(CD103)β<sub<7</sub< misc E-cadherin misc T<sub<RM</sub< cells misc immunotherapy misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc CD103 misc integrin misc α<sub<E</sub<(CD103)β<sub<7</sub< misc E-cadherin misc T<sub<RM</sub< cells misc immunotherapy misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc CD103 misc integrin misc α<sub<E</sub<(CD103)β<sub<7</sub< misc E-cadherin misc T<sub<RM</sub< cells misc immunotherapy misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Cancers
hierarchy_parent_id	614095670
hierarchy_top_title	Cancers
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)614095670 (DE-600)2527080-1
title	Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer
ctrlnum	(DE-627)DOAJ018726534 (DE-599)DOAJ14c9772ee521489ab59b771bb99b4637
title_full	Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer
author_sort	Johanna C. Hoffmann
journal	Cancers
journalStr	Cancers
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
author_browse	Johanna C. Hoffmann Michael P. Schön
container_volume	13
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Johanna C. Hoffmann
doi_str_mv	10.3390/cancers13246211
author2-role	verfasserin
title_sort	integrin α<sub<e</sub<(cd103)β<sub<7</sub< in epithelial cancer
callnumber	RC254-282
title_auth	Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer
abstract	Interactions of both the innate and the adaptive immune system with tumors are complex and often influence courses and therapeutic treatments in unanticipated ways. Based on the concept that CD8<sup<+</sup<T cells can mediate important antitumor effects, several therapies now aim to amplify their specific activity. A subpopulation of CD8<sup<+</sup< tissue-resident T lymphocytes that express the α<sub<E</sub<(CD103)β<sub<7</sub< integrin has raised particular interest. This receptor presumably contributes to the recruitment and retention of tumor-infiltrating immune cells through interaction with its ligand, E-cadherin. It appears to have regulatory functions and is thought to be a component of some immunological synapses. In TGF-rich environments, the α<sub<E</sub<(CD103)β<sub<7</sub</E-cadherin-interaction enhances the binding strength between tumor cells and infiltrating T lymphocytes. This activity facilitates the release of lytic granule contents and cytokines as well as further immune responses and the killing of target cells. Expression of α<sub<E</sub<(CD103)β<sub<7</sub< in some tumors is associated with a rather favorable prognosis, perhaps with the notable exception of squamous cell carcinoma of the skin. Although epithelial skin tumors are by far the most common tumors of fair-skinned people, there have been very few studies on the distribution of α<sub<E</sub<(CD103)β<sub<7</sub< expressing cells in these neoplasms. Given this background, we describe here that α<sub<E</sub<(CD103)β<sub<7</sub< is scarcely present in basal cell carcinomas, but much more abundant in squamous cell carcinomas with heterogeneous distribution. Notwithstanding a substantial number of studies, the role of α<sub<E</sub<(CD103)β<sub<7</sub< in the tumor context is still far from clear. Here, we summarize the essential current knowledge on α<sub<E</sub<(CD103)β<sub<7</sub< and outline that it is worthwhile to further explore this intriguing receptor with regard to the pathophysiology, therapy, and prognosis of solid tumors.
abstractGer	Interactions of both the innate and the adaptive immune system with tumors are complex and often influence courses and therapeutic treatments in unanticipated ways. Based on the concept that CD8<sup<+</sup<T cells can mediate important antitumor effects, several therapies now aim to amplify their specific activity. A subpopulation of CD8<sup<+</sup< tissue-resident T lymphocytes that express the α<sub<E</sub<(CD103)β<sub<7</sub< integrin has raised particular interest. This receptor presumably contributes to the recruitment and retention of tumor-infiltrating immune cells through interaction with its ligand, E-cadherin. It appears to have regulatory functions and is thought to be a component of some immunological synapses. In TGF-rich environments, the α<sub<E</sub<(CD103)β<sub<7</sub</E-cadherin-interaction enhances the binding strength between tumor cells and infiltrating T lymphocytes. This activity facilitates the release of lytic granule contents and cytokines as well as further immune responses and the killing of target cells. Expression of α<sub<E</sub<(CD103)β<sub<7</sub< in some tumors is associated with a rather favorable prognosis, perhaps with the notable exception of squamous cell carcinoma of the skin. Although epithelial skin tumors are by far the most common tumors of fair-skinned people, there have been very few studies on the distribution of α<sub<E</sub<(CD103)β<sub<7</sub< expressing cells in these neoplasms. Given this background, we describe here that α<sub<E</sub<(CD103)β<sub<7</sub< is scarcely present in basal cell carcinomas, but much more abundant in squamous cell carcinomas with heterogeneous distribution. Notwithstanding a substantial number of studies, the role of α<sub<E</sub<(CD103)β<sub<7</sub< in the tumor context is still far from clear. Here, we summarize the essential current knowledge on α<sub<E</sub<(CD103)β<sub<7</sub< and outline that it is worthwhile to further explore this intriguing receptor with regard to the pathophysiology, therapy, and prognosis of solid tumors.
abstract_unstemmed	Interactions of both the innate and the adaptive immune system with tumors are complex and often influence courses and therapeutic treatments in unanticipated ways. Based on the concept that CD8<sup<+</sup<T cells can mediate important antitumor effects, several therapies now aim to amplify their specific activity. A subpopulation of CD8<sup<+</sup< tissue-resident T lymphocytes that express the α<sub<E</sub<(CD103)β<sub<7</sub< integrin has raised particular interest. This receptor presumably contributes to the recruitment and retention of tumor-infiltrating immune cells through interaction with its ligand, E-cadherin. It appears to have regulatory functions and is thought to be a component of some immunological synapses. In TGF-rich environments, the α<sub<E</sub<(CD103)β<sub<7</sub</E-cadherin-interaction enhances the binding strength between tumor cells and infiltrating T lymphocytes. This activity facilitates the release of lytic granule contents and cytokines as well as further immune responses and the killing of target cells. Expression of α<sub<E</sub<(CD103)β<sub<7</sub< in some tumors is associated with a rather favorable prognosis, perhaps with the notable exception of squamous cell carcinoma of the skin. Although epithelial skin tumors are by far the most common tumors of fair-skinned people, there have been very few studies on the distribution of α<sub<E</sub<(CD103)β<sub<7</sub< expressing cells in these neoplasms. Given this background, we describe here that α<sub<E</sub<(CD103)β<sub<7</sub< is scarcely present in basal cell carcinomas, but much more abundant in squamous cell carcinomas with heterogeneous distribution. Notwithstanding a substantial number of studies, the role of α<sub<E</sub<(CD103)β<sub<7</sub< in the tumor context is still far from clear. Here, we summarize the essential current knowledge on α<sub<E</sub<(CD103)β<sub<7</sub< and outline that it is worthwhile to further explore this intriguing receptor with regard to the pathophysiology, therapy, and prognosis of solid tumors.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	24, p 6211
title_short	Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer
url	https://doi.org/10.3390/cancers13246211 https://doaj.org/article/14c9772ee521489ab59b771bb99b4637 https://www.mdpi.com/2072-6694/13/24/6211 https://doaj.org/toc/2072-6694
remote_bool	true
author2	Michael P. Schön
author2Str	Michael P. Schön
ppnlink	614095670
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/cancers13246211
callnumber-a	RC254-282
up_date	2024-07-03T19:35:00.642Z
_version_	1803587735417520128
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ018726534</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412095357.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/cancers13246211</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ018726534</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ14c9772ee521489ab59b771bb99b4637</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Johanna C. Hoffmann</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Interactions of both the innate and the adaptive immune system with tumors are complex and often influence courses and therapeutic treatments in unanticipated ways. Based on the concept that CD8<sup<+</sup<T cells can mediate important antitumor effects, several therapies now aim to amplify their specific activity. A subpopulation of CD8<sup<+</sup< tissue-resident T lymphocytes that express the α<sub<E</sub<(CD103)β<sub<7</sub< integrin has raised particular interest. This receptor presumably contributes to the recruitment and retention of tumor-infiltrating immune cells through interaction with its ligand, E-cadherin. It appears to have regulatory functions and is thought to be a component of some immunological synapses. In TGF-rich environments, the α<sub<E</sub<(CD103)β<sub<7</sub</E-cadherin-interaction enhances the binding strength between tumor cells and infiltrating T lymphocytes. This activity facilitates the release of lytic granule contents and cytokines as well as further immune responses and the killing of target cells. Expression of α<sub<E</sub<(CD103)β<sub<7</sub< in some tumors is associated with a rather favorable prognosis, perhaps with the notable exception of squamous cell carcinoma of the skin. Although epithelial skin tumors are by far the most common tumors of fair-skinned people, there have been very few studies on the distribution of α<sub<E</sub<(CD103)β<sub<7</sub< expressing cells in these neoplasms. Given this background, we describe here that α<sub<E</sub<(CD103)β<sub<7</sub< is scarcely present in basal cell carcinomas, but much more abundant in squamous cell carcinomas with heterogeneous distribution. Notwithstanding a substantial number of studies, the role of α<sub<E</sub<(CD103)β<sub<7</sub< in the tumor context is still far from clear. Here, we summarize the essential current knowledge on α<sub<E</sub<(CD103)β<sub<7</sub< and outline that it is worthwhile to further explore this intriguing receptor with regard to the pathophysiology, therapy, and prognosis of solid tumors.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CD103</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">integrin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">α<sub<E</sub<(CD103)β<sub<7</sub<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">E-cadherin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">T<sub<RM</sub< cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael P. Schön</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cancers</subfield><subfield code="d">MDPI AG, 2010</subfield><subfield code="g">13(2021), 24, p 6211</subfield><subfield code="w">(DE-627)614095670</subfield><subfield code="w">(DE-600)2527080-1</subfield><subfield code="x">20726694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:24, p 6211</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/cancers13246211</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/14c9772ee521489ab59b771bb99b4637</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6694/13/24/6211</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2021</subfield><subfield code="e">24, p 6211</subfield></datafield></record></collection>
score	7.399599

Nicht das Richtige dabei?

Schreiben Sie uns!

Integrin α<sub<E</sub<(CD103)β<sub<7</sub< in Epithelial Cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?